Novo Nordisk says Wegovy shows greater weight loss than Eli Lilly's rival pill

A cross-trial comparison shows Novo's oral semaglutide produced 3.2 percentage points more weight loss than Foundayo, with Eli Lilly's drug seeing significantly higher dropout rates due to side effects.

Go to News Site